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Primary ciliary dyskinesia (PCD) is a genetic condition resulting in bronchiectasis. Exhaled gas
nitric oxide (FENO) is reduced in PCD. A model of pulmonary NO exchange dynamics can be used
to demonstrate relative contributions of bronchial (J0awNO) and peripheral airway (CalvNO) NO
to the final FENO concentration. The aim of this study was to compare bronchial and peripheral
airway contribution to FENO in patients with PCD, non-PCD bronchiectasis and healthy controls
in order to establish the source of present FENO in these conditions and to compare these with
severity of disease. NO was measured at 50, 100, and 200 ml/s using an NO analyser (NiOx
Sweden). J0awNO and CalvNO were calculated according to a model of pulmonary exchange
dynamics. PCD patients had reduced levels of J0awNO compared to healthy controls whereas
patients with non-PCD bronchiectasis had elevated J0awNO levels. There was no difference in
CalvNO between the three groups. In the disease groups CalvNO correlated negatively with
FEV1. In conclusion patients with PCD had significantly reduced FENO at all expiratory flow
rates. This was due to a significantly low bronchial NO. In contrast, peripheral airway NO
was increased with more severe disease.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Bronchiectasis is defined as abnormal chronic dilatation of
one or more bronchi caused by a structural abnormality of
the bronchial wall.1 Symptoms include recurrent lower
respiratory tract infections, chronic cough and regular
sputum production. There are various aetiologies which
include primary ciliary dyskinesia (PCD) which is an7 351 8337; fax: þ44 207 351
.uk (R. Wilson).
8 Elsevier Ltd. All rights reservedautosomal recessive condition. In this condition abnormal
or absent beating of cilia results in poor mucociliary
clearance. In the bronchial tree recurrent lower respiratory
tract infections cause bronchiectasis; and abnormal ciliary
beat at other sites causes rhinosinusitis, middle ear disease
and impaired fertility.
Measurement of the gas nitric oxide (NO) may be a useful
way to assess airway inflammation. Fractional exhaled nitric
oxide (FENO) is raised in patients with inflammatory airways
diseases such as asthma. This test is rapid, non-invasive,
direct and repeatable.2 FENO andnasal NOare reduced in PCD
and can be used as a screening test for the condition.3,4 Most
of the available information on PCD is on nasal NO and the.
NO in PCD and bronchiectasis 701mechanism behind the reduction of FENO has not yet been
identified. FENO is also reduced in patientswith cystic fibrosis
(CF) another genetic condition associated with bronchiec-
tasis in whichmucociliary clearance is impaired.5 It has been
hypothesised that low NO in PCD may be due to reduced
activity of the enzyme nitric oxide synthase (NOS).6
By measuring NO at multiple expiratory flow rates a two-
compartment model of pulmonary NO exchange dynamics
can be used to demonstrate relative contributions of
bronchial (J0awNO) and peripheral airway (CalvNO) NO to the
final FENO concentration.
7 This model divides the lung into
two compartments. The first compartment is the alveolar
region where locally produced NO mixes with inhaled NO
whilst some NO is destroyed or diffuses away. This balance
remains at a steady concentration independent of expira-
tory flow rate. The second compartment is the bronchial
region where NO is affected by the diffusion capacity of the
airway and the airway wall NO concentration. Together
these are known as the total airway NO flux (J0awNO) and
are dependent on expiratory flow rate. This model has been
used to demonstrate that elevated NO in asthma originates
predominantly from the bronchial region of the lung
whereas in alveolitis and in COPD J0awNO is similar to normal
controls but CalvNO is elevated.
8
Applying this model in PCD will allow us to establish in
which compartments of the lung NO is absent from and
present in, and will therefore allow us to elucidate further
the mechanism behind this reduction of FENO. We suggest
that NO is related directly to the cilia themselves and their
movement. Since cilia are absent from the terminal bron-
chioles and alveolar epithelium, we hypothesise that the
NO contribution from this area will be similar to the two
other groups and will be related to disease activity and
severity. Comparison of PCD with non-PCD bronchiectasis
where neutrophilic inflammation, oxidative stress and
mucus production are all present will allow exclusion of
these factors as causes of low NO.
Aim
The aim of this study was to compare bronchial and
peripheral airway contribution to FENO in patients with
PCD, non-PCD bronchiectasis and healthy controls in order
to establish the source of FENO present in these conditions
and to compare these with severity of disease.
Methods
Ethics
This study was approved by the Royal Brompton Hospital
Ethics Committee and all subjects gave written informed
consent.
Study design
Twenty patients with PCD and 20 patients with non-PCD
bronchiectasis were recruited from the infection firm at the
Royal Brompton hospital, and were asked to perform FENO
tests at variable flow rates. The relative contribution ofJ0awNO and CalvNO were calculated and the results
compared to those of 20 healthy controls.
NO was compared with age (in years), gender, height (in
metres), weight (in kilograms), sputum bacteriology (as
a marker of disease severity ); patients with P seudomonas
aeruginosa have more severe bronchiectasis,9,10 treatment
with inhaled corticosteroids, requirement for antibiotic
treatment, ciliary beat frequency, beat pattern and ultra-
structure. FEV1 (in litres) was used as a measure of severity
of bronchiectasis as the time since the most recent CT scan
in the PCD group was on average 11 years and repeat CT
scans were not felt to be ethically justified for this study
due to the radiation risk.
Study subjects
Patients were recruited during the performance of two
studies. The first was to determine the aetiology of bron-
chiectasis in all new patients admitted to the hospital for
a series of investigations from March 2005 to March 2007.11
The second enrolled consecutive outpatients between 1st
January 2006 and 1st June 2006 to investigate inflammatory
markers in bronchiectasis.12 All PCD patients with
confirmed ultrastructural defect who were seen during this
time were included in the study. A group of 20 non-PCD
bronchiectasis patients were chosen from the remaining
patients. They were chosen as the best match to each of
the PCD patients on the following criteria: age, gender,
height, weight, treatment with corticosteroid medication
and requirement for treatment with oral antibiotics at the
end of visit/assessment. Patients were selected without
knowledge of NO results. Current smokers (smoked within
the 2 months preceding the study) were not included in any
group as smoking has been shown to alter FENO.
13 Hospital
staff of similar age and gender to the PCD group were
recruited as normal controls.
Primary ciliary dyskinesia (nZ 20)
PCD was confirmed by nasal brush biopsy. Samples were
analysed for cilia beat frequency and beat pattern under
light microscopy as described by Rutland and colleagues.14
Briefly, a cytology brush was used to scrape epithelial cells
from the inferior turbinate. Ciliated epithelial strips were
visualised immediately under a light microscope to assess
ciliary beat pattern. Ciliary beat frequency was measured
using a photometer with a small diaphragm. The electrical
signal generated by cilia interrupting light was converted
into beat frequency in Hertz. Samples were fixed in glu-
teraldehyde and an ultrastructural defect of the cilia was
confirmed by electron microscopy.15
Non-PCD bronchiectasis (nZ 20)
Bronchiectasis was confirmed by high resolution CT scan
according to standard criteria.16
All patients from both groups had undergone investiga-
tion of their condition to determine the cause of their
bronchiectasis.11 Patients with CF were excluded from this
group. Patients with a history of asthma were also excluded
as NO has been shown to be elevated in this condition.2 In
order to investigate PCD, nasal mucociliary clearance was
measured by the saccharin test.17 Patients with nasal
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of PCD had a nasal brush biopsy. A sweat test was used as
a screening test for CF. This was followed by CF genotyping
from a blood sample if the sweat test was positive (Naþ, Cl
>90 mm/l) or borderline (Naþ and Cl 70e90 mm/l), or
other features of the case such as upper lobe bronchiectasis
or a family history suggested the diagnosis.
Healthy controls
Volunteers with no history of respiratory disease and free
from bacterial or viral infections for 8 weeks before study
were used as healthy controls.
Experimental tests
NO was measured at 50, 100, and 200 ml/s using an NO
analyser (NiOx, Aerocrine, Sweden). Our experience has
shown us that bronchiectasis patients find flow rates
>200 ml/s difficult to perform resulting in less reproducible
results (unpublished finding). Two measurements were
performed at each of the three flow rates according to ATS
standards.18 Actual flow, FENO and ambient NO were
recorded for each measurement. Nasal NO was also
measured according to ATS standards using a chemilumi-
nescent NO analyser (LR 2000 Logan Research Ltd,
Rochester, UK). The subject was asked to inspire and hold
their breath (in order to close the soft palate) for as long as
possible holding a nasal probe, attached to the analyser, in
their nostril so that it formed a seal. The machine draws air
from the nose at 250 ml/min into the analyser. Nasal NO
was measured where there was a plateau in NO concen-
tration. The LR2000 NO analyser was used for the nasal NO
as it simultaneously measures CO2 at the same time as NO.
This allows the observer to check the patient’s breath hold
technique.
Data analysis
The mean of the two FENO measurements at each flow rate
measured was used to calculate J0awNO and CalvNO using the
linear equation of Tsoukias and George as a two compart-
mental model of pulmonary exchange dynamics.7
VNOZJ0awNO þ VE CalvNO
where VNO (pl/s) is NO output during exhalation (exhaled
NO concentration (ppb)  exhalation flow rate (l/s)),
J0awNO (pl/s) is total NO flux in the airways, VE (ml/s) is
exhalation flow rate, and CalvNO (ppb) is steady-state NO
concentration in alveolar air.
A regression line was drawn between NO output and flow
rate at expiratory flows (50 ml/s, 100 ml/s and 200 ml/s) as
shown in Fig. 1. The slope of this regression line was taken
to represent the alveolar NO concentration (CalvNO) and the
intercept the bronchial NO output (J0awNO). Where CalvNO
was calculated to be less than zero, a zero was used in
reporting of results and for data analysis.
The data was evaluated using commercially available
statistical analysis software (SPSS). Where data was nor-
mally distributed, the values are reported as the mean and
95% confidence interval. The outcome variables (J0awNO
and CalvNO) were found to be approximately normallydistributed on normal plots after log transformation.
Therefore the natural log of the value was used for statis-
tical analysis. Ordinary least squares regression models
were used to look at univariate relationships between
logJ0awNO / logCalvNO and patient characteristics. A Stu-
dent’s t-test or ANOVA was used to compare groups and
linear regression analysis was used to assess relationship
between variables. Where log transformation was per-
formed the geometric mean and standard deviation were
reported in the results. Differences were considered to be
significant when probability values were less than or equal
to 0.05.
Results
Demographics and nitric oxide
The aetiology of patients in the bronchiectasis group were
idiopathic (7), post infective (12) and alpha 1 anti-trypsin
deficiency (1). The age, height and weight of these patients
were similar to normal controls and patients with PCD.
There was a female predominance in all three groups. This
data is shown in Table 1. There was no relationship
between CalvNO or J
0awNO and age, gender, height or weight
(data not shown).
There was a significant difference in FENO between the
three groups at all expiratory flow rates (p < 0.01). A
summary of the results is shown in Table 1. PCD patients
had reduced J0awNO and patients with non-PCD bronchi-
ectasis had elevated J0awNO compared to normal volun-
teers. The distribution of the data is illustrated in Fig. 2.
There was no significant difference in CalvNO between the
groups.
Nasal NO was low in all PCD patients compared to other
bronchiectasis patients and normal controls. This data is
illustrated in Fig. 3 and shows that there was no overlap
between PCD patient values and those of other groups.
There was no correlation between nasal NO and J0awNO or
CalvNO
Demographics, lung function and bacteriology
Patients with PCD had significantly worse FEV1 than those
with non-PCD bronchiectasis (p < 0.01). There was a corre-
lation between FEV1 and age in the disease groups. There
was a negative correlation between CalvNO and FEV1 in
the disease groups. This correlation is shown in Fig. 4
(rZ 0.43, p < 0.01). There was no relationship between
J0awNO and FEV1.
Sputum samples cultured Pseudomonas aeruginosa in
five PCD patients. Five patients had non-pseudomonas
species cultured. These were Haemophilus influenzae (3),
Moraxella catarrhalis (2), Streptococcus pneumoniae (1),
Staphylococcus aureus (1); some patients grew more than
one bacterial species. The remaining ten patients had no
bacterial growth in their sputum or were not productive of
sputum at the time of study. In the non-PCD group 4
patients grew P. aeruginosa in their sputum. Nine patients
grew other bacteria. These were S. aureus (4), H. influen-
zae (3), and S. pneumoniae (2). Seven patients had no
bacterial growth or were not productive of sputum at the
Table 1 Comparison of nitric oxide and group demographics in subjects with PCD, non-PCD bronchiectasis and healthy
controls.
Healthy controls PCD Non-PCD bronchiectasis p value
n 20 20 20
Age (years) mean (95% CI) 37 (30e43) 40 (32e45) 41 (35e48) >0.05
Male (% group) 6 (30) 6 (30) 6 (30) >0.05
Height (cm) mean (95% CI) 168 (165e172) 168 (162e170) 164 (161e170) >0.05
Weight (kg) mean (95% CI) 64 (60e70) 66 (60e73) 66 (59e71) >0.05
FEV1 (l) mean (95% CI) - 1.8 (1.5e2.2) 2.5 (2.0e3.0) <0.01
Requirement for antibiotics (% group) 0 8 (40) 8 (40) >0.05
Inhaled corticosteroids (% group) 0 15 (75) 14 (70) >0.05
Nasal NO (ppb) mean (95% CI) 639 (422e890) 49 (34e 64) 892 (528e976) <0.01
FENO50 (ppb) mean (95% CI) 13.9 (11.7e16.4) 7.1 (5.7e8.8) 21.1 (15.5e28.8) <0.01
FENO100 (ppb) mean (95% CI) 8.0 (6.7e9.6) 5.0 (4.1e6.2) 12.8 (9.7e16.9) <0.01
FENO200 (ppb) mean (95% CI) 5.5 (4.9e6.3) 3.8 (3.1e4.6) 7.6 (5.6e10.2) <0.01
J0awNO (pl/s) mean (95% CI) 567 (455e706) 213 (150e299) 925 (652e1300) <0.01
CalvNO (ppb) mean (95% CI) 2.7 (2.2e3.3) 2.6 (2.1e3.4) 2.6 (1.3e5.0) >0.05
Statistical significance was calculated by ANOVA.
NO in PCD and bronchiectasis 703time of study. There was no significant difference in CalvNO
or J0awNO when comparing patients who grew P. aeruginosa,
other bacteria, or no bacteria (p > 0.05).
Cilia
All PCD patients had an ultrastructural defect of their cilia
confirmed by electron microscopy. These were: absence of
both inner and outer dynein arms (6), outer dynein arm
defect (6), radial spoke defect combined with an absence
of inner dynein arms (3), transposition defect (3), and inner
dynein arm defect (2). J0awNO, CalvNO and nasal NO were
similar in all defects.
In 11 PCD patients with moving cilia the average ciliary
beat frequency at diagnosis was 10.0 Hz (9.4) (normal range
11e16 Hz). Beat pattern was reported as stiff (5), slow (4),
and dyskinetic (6). More than one description was used per
sample. There was no correlation between beat frequency
and J0awNO, CalvNO, or nasal NO, rZ 0.29, pZ 0.38,
rZ 0.13 pZ 0.70, rZ 0.26, pZ 0.44 respectively. In
nine patients the cilia were completely static (0 Hz). There
was no significant difference in J0awNO, CalvNO, or nasal NO
mean (95% CI) between the group with completely static
cilia at diagnosis (245 pl/s (147e407), 2.4 ppb (1.7e3.3),
53.5 ppb (18.6e88.4)) and those with some movement
(181 pl/s (109e330), 2.7 ppb (1.9e4.0), 42.8 ppb (28.1e
57.4)).0
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Figure 1 The regression line used to calculate relative contributMedication
The majority of patients in both groups were taking inhaled
corticosteroids. There was no difference in CalvNO or JNO in
patients taking corticosteroids compared to those who
were not p > 0.05.
Table 2 shows the J0awNO and CalvNO of 8 patients
requiring antibiotic treatment in the two patient groups
compared to 12 patients who did not require treatment.
There was no significant difference between J0awNO and
CalvNO values in those patients who were prescribed anti-
biotics and those who were not p > 0.05.
Discussion
We have found that low FENO in PCD was due to a signifi-
cantly low bronchial NO rather than peripheral airway NO
which was similar to healthy controls. These findings are
similar to previous findings in paediatric patients.19 Low
nasal NO in PCD was first described by Lundberg over
a decade ago and has been confirmed by several authors
subsequently.3,4,20e22 Similarly, low FENO has been demon-
strated at flow rates of 50 ml/s and 200 ml/s.22,23 The
results of the present study are comparable with these
findings. Horvath et al. showed that FENO in adult PCD
patients was reduced compared to normal controls and150 200 250
sured V
E
(ml/s)
ions of nitric oxide in a patient with primary ciliary dyskinesia.
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Figure 2 Box and whisker plot comparison of proximal
airway nitric oxide in 20 healthy controls, 20 patients with
primary ciliary dyskinesia and 20 patients with non-PCD bron-
chiectasis. The box represents the interquartile range inter-
sected by the median. The whiskers represent the range of
data. There is a significant difference between all three
groups. PCD, primary ciliary dyskinesia; J0awNO, maximal
airway nitric oxide.
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elevated. The authors suggested that nasal NO and FENO in
combination improve the specificity of NO as a screening
test for PCD from 93% to 98%.3 For example, structural
abnormalities such as nasal polyps can lead to a low nasal0.00
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Figure 3 Box and whisker plot of nasal nitric oxide in 20
healthy controls, 20 patients with primary ciliary dyskinesia
and 20 patients with non-PCD bronchiectasis. The box repre-
sents the interquartile range intersected by the median. The
whiskers represent the range of data. There is a significant
difference between the PCD group and healthy controls and
non-PCD bronchiectasis patients. PCD, primary ciliary dyski-
nesia; NO, nitric oxide.NO. Based on the results of the present study we suggest
that a low flow rate such as 50 ml/s will provide the largest
difference between PCD patients and non-PCD bronchiec-
tasis patients in screening tests when used in combination
with nasal NO. This flow rate has the highest contribution of
NO from the proximal airways and is also recommended by
the American Thoracic Society.18 Neither FENO nor J
0awNO
should be used alone as screening tests as there was
considerable overlap between PCD patients and normal
controls.
The present study is the first to compare PCD to non-PCD
bronchiectasis patients as well as controls. We have shown
in that CalvNO but not J
0awNO correlated negatively with
FEV1 in the two disease groups. Two previous papers have
investigated NO in PCD at multiple flow rates.19,24 The first
study showed reduced J0awNO and CalvNO in a population of
15 adolescent PCD patients compared to normal controls.
There was a negative correlation between J0awNO and FEV1.
The second study in paediatric PCD patients compared to
healthy controls showed no correlation between either of
the NO parameters and FEV1. The adult population in the
present study, who therefore have more severe disease,
seems to be the most likely explanation for these
differences.
The calculation of CalvNO requires that some assump-
tions are made about the exchange dynamics of the lungs.
Some of these assumptions are difficult to substantiate in
disease states.25 For example the linear relationship
between flow rate and FENO is only present above flow rates
which are 5  DawNO. As DawNO is unknown in PCD the
authors must assume this to be true. The apparent linear
relationship between VENO and VE for each patient suggests
this is the case in most patients, although in a few excep-
tions the relationship between VENO and VE may have been
better described by a curve. This was true in all three
groups (controls, PCD and non-PCD bronchiectasis).
In addition J0awNO can only be used to express the flux
from the airways in conditions where the alveolar concen-
tration is very small compared to the airway concentration
(<2%).25 In PCD this does not appear to be true due to the
low airway concentration and normal peripheral airway
concentration and therefore the slope of the regression line
should be interpreted more rigorously as DawNO
(Caw  CalvNO ); i.e. peripheral airway NO may contami-
nate the bronchial NO parameter and it is not known
whether the differences observed for this term were due to
differences in airway wall concentration or differences in
transfer factor. The latter could be influenced by excess
mucus production in this disorder.
A reduction of NOSII or defect in expression would
explain the finding of a low level of J0awNO in all PCD
patients regardless of requirement for antibiotic treat-
ment. NOSII inhibitors slow bovine ciliary beat frequency
and this effect can be reversed with L-arginine, suggesting
that the NOSII pathway is involved in the regulation of
ciliary beat frequency.26 NOSIII has been identified as the
main NOS isoform that is expressed in normal human nasal
mucosa.27 In murine epithelia NOSIII immunoreactivity has
been demonstrated within ciliated epithelium, and was
shown to be associated with the basal microtubule
membrane of the cilia.28 However in the present study
there was no relationship between NO and whether some
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Figure 4 Regression line showing a negative correlation between peripheral airway nitric oxide and FEV1 in patients with primary
ciliary dyskinesia and non-PCD bronchiectasis. CalvNO, peripheral airway nitric oxide; FEV1, forced expiratory volume in one
second.
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may be due to the multiple isoforms of NOS, other sources
of NO besides ciliated epithelial cells, or due to the small
number of patients in the study. Therefore we hypothesise
that in PCD a reduction of NOSII and or NOSIII activity exists,
which is in some way related to the ultrastructural abnor-
mality. Since cilia are absent from the terminal bronchioles
and alveolar epithelium, similar CalvNO results would be
expected in PCD and the two other groups. The NO from
this site may be from another source such as alveolar
macrophages.
In conclusion patients with PCD had significantly reduced
FENO at all expiratory flow rates. This was due to a signifi-
cantly low bronchial NO compared to healthy controls and
other bronchiectasis patients. However, there was an
overlap with normal controls which did not occur with nasalTable 2 Comparison of nitric oxide in subjects with
primary ciliary dyskinesia and bronchiectasis of another
cause who were prescribed antibiotics.
Required antibiotic
treatment
Did not require
antibiotic
treatment
PCD
n 8 12
J0awNO (pl/s)
mean (95% CI)
215 (107e433) 211 (134e330)
CalvNO (ppb)
mean (95% CI)
3.4 (2.2e5.1) 2.2 (1.6e3.0)
Non-PCD bronchiectasis
n 8 12
J0awNO (pl/s)
mean (95% CI)
1466 (829e2618) 658 (459e953)
CalvNO (ppb)
mean (95% CI)
2.0 (0.9e11.8) 3.1 (2.5e3.8)NO. The use of a low flow rate such as 50 ml/s will provide
the most marked difference between PCD patients and
patients without PCD in screening tests. Peripheral airway
NO was increased with more severe disease whereas bron-
chial NO was unchanged, suggesting low NO in PCD is
related to the structural abnormality of the cilia.
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